PHMMF Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -11.5% compared to Pharma Mar SA's net margin of --. Pharma Mar SA's return on equity of 17.03% beat CEL-SCI Corp.'s return on equity of -266.61%.

Pharma Mar SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Pharma Mar SA, analysts believe CEL-SCI Corp. is more attractive than Pharma Mar SA.

Pharma Mar SA has a beta of 0.498, which suggesting that the stock is 50.224% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Pharma Mar SA has a quarterly dividend of $0.92 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharma Mar SA pays 43.51% of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend. Pharma Mar SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharma Mar SA quarterly revenues are $41.7M, which are larger than CEL-SCI Corp. quarterly revenues of --. Pharma Mar SA's net income of -$4.8M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Pharma Mar SA's price-to-earnings ratio is 40.53x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharma Mar SA is 7.65x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Grifols SA has a net margin of -11.5% compared to Pharma Mar SA's net margin of 7.69%. Pharma Mar SA's return on equity of 17.03% beat Grifols SA's return on equity of 5.73%.

Pharma Mar SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Grifols SA has an analysts' consensus of $11.25 which suggests that it could grow by 27.12%. Given that Grifols SA has higher upside potential than Pharma Mar SA, analysts believe Grifols SA is more attractive than Pharma Mar SA.

Pharma Mar SA has a beta of 0.498, which suggesting that the stock is 50.224% less volatile than S&P 500. In comparison Grifols SA has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.935%.

Pharma Mar SA has a quarterly dividend of $0.92 per share corresponding to a yield of 0%. Grifols SA offers a yield of 1.96% to investors and pays a quarterly dividend of $0.17 per share. Pharma Mar SA pays 43.51% of its earnings as a dividend. Grifols SA pays out -- of its earnings as a dividend. Pharma Mar SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharma Mar SA quarterly revenues are $41.7M, which are smaller than Grifols SA quarterly revenues of $2.2B. Pharma Mar SA's net income of -$4.8M is lower than Grifols SA's net income of $167.6M. Notably, Pharma Mar SA's price-to-earnings ratio is 40.53x while Grifols SA's PE ratio is 14.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharma Mar SA is 7.65x versus 0.72x for Grifols SA. Usually stocks with elevated PS ratios are considered overvalued.

Laboratorios Farmaceúticos Rovi SA has a net margin of -11.5% compared to Pharma Mar SA's net margin of 27.56%. Pharma Mar SA's return on equity of 17.03% beat Laboratorios Farmaceúticos Rovi SA's return on equity of 20.71%.

Pharma Mar SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Laboratorios Farmaceúticos Rovi SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharma Mar SA has higher upside potential than Laboratorios Farmaceúticos Rovi SA, analysts believe Pharma Mar SA is more attractive than Laboratorios Farmaceúticos Rovi SA.

Pharma Mar SA has a beta of 0.498, which suggesting that the stock is 50.224% less volatile than S&P 500. In comparison Laboratorios Farmaceúticos Rovi SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Pharma Mar SA has a quarterly dividend of $0.92 per share corresponding to a yield of 0%. Laboratorios Farmaceúticos Rovi SA offers a yield of 1.66% to investors and pays a quarterly dividend of $1.09 per share. Pharma Mar SA pays 43.51% of its earnings as a dividend. Laboratorios Farmaceúticos Rovi SA pays out 28.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharma Mar SA quarterly revenues are $41.7M, which are smaller than Laboratorios Farmaceúticos Rovi SA quarterly revenues of $245.9M. Pharma Mar SA's net income of -$4.8M is lower than Laboratorios Farmaceúticos Rovi SA's net income of $67.8M. Notably, Pharma Mar SA's price-to-earnings ratio is 40.53x while Laboratorios Farmaceúticos Rovi SA's PE ratio is 24.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharma Mar SA is 7.65x versus 4.20x for Laboratorios Farmaceúticos Rovi SA. Usually stocks with elevated PS ratios are considered overvalued.

Oryzon Genomics SA has a net margin of -11.5% compared to Pharma Mar SA's net margin of --. Pharma Mar SA's return on equity of 17.03% beat Oryzon Genomics SA's return on equity of -2.73%.

Pharma Mar SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Oryzon Genomics SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Pharma Mar SA has higher upside potential than Oryzon Genomics SA, analysts believe Pharma Mar SA is more attractive than Oryzon Genomics SA.

Pharma Mar SA has a beta of 0.498, which suggesting that the stock is 50.224% less volatile than S&P 500. In comparison Oryzon Genomics SA has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.368%.

Pharma Mar SA has a quarterly dividend of $0.92 per share corresponding to a yield of 0%. Oryzon Genomics SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pharma Mar SA pays 43.51% of its earnings as a dividend. Oryzon Genomics SA pays out -- of its earnings as a dividend. Pharma Mar SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pharma Mar SA quarterly revenues are $41.7M, which are larger than Oryzon Genomics SA quarterly revenues of --. Pharma Mar SA's net income of -$4.8M is lower than Oryzon Genomics SA's net income of $393.5K. Notably, Pharma Mar SA's price-to-earnings ratio is 40.53x while Oryzon Genomics SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pharma Mar SA is 7.65x versus 440.67x for Oryzon Genomics SA. Usually stocks with elevated PS ratios are considered overvalued.